![Quiver Logo](/static/img/logo-icon.png)
![OCSAW logo](https://quiver-logos.s3.us-east-2.amazonaws.com/ocsaw.png)
Oculis Holding AG Warrants
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OCSAW Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of OCSAW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OCSAW's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to OCSAW
Recent picks made for OCSAW stock on CNBC
ETFs with the largest estimated holdings in OCSAW
Flights by private jets registered to OCSAW
![Quiver Logo](/static/img/logo-icon.png)